Cancer Cachexia Market Size to be USD 3.6 Billion by 2034; Market is Amplified due to Growing Awareness of Cachexia’s Impact

Download Sample

Published Date: March 2025

Cancer cachexia market refers to the market for treatments and therapies aimed at managing or mitigating this condition in cancer patients. Cancer cachexia is a complex metabolic syndrome associated with cancer, characterized by severe weight loss, muscle wasting, and loss of appetite. Growing awareness among healthcare professionals and patients of the severe consequences of cancer cachexia, is anticipated to drive target market growth.

Cancer Cachexia Market Segmentation Analysis:

By Product	Progestogens, Corticosteroids, Combination Therapies, and Others
By Mechanism of Action	Appetite Stimulators and Weight Loss Stabilizers
By Distribution Channel	Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy

Cancer Cachexia Market??????? Report Highlights:

Cancer cachexia market size was estimated for USD 2.45 Billion in 2024.
The market is look forward to grow at USD 3.6 Billion at a CAGR of 4.3% by 2034.
Based on product, the market is dominated by the progestogens segment.
On the basis of mechanism of action, the appetite stimulators segment is expected to hold the largest cancer cachexia market share.
Hospital pharmacies segment have the largest market share in the market, into distribution channel way.
North America holds the major market share.

Cancer Cachexia Market Dynamics:

Growing Factor	Challenge Factor	Market Trend
Expanding Cancer Treatment Infrastructure	Complex Pathophysiology of Cachexia	Collaboration Between Pharmaceutical and Biotechnology Companies

Cancer Cachexia Market Key Highlights

In February 2024, Meta Fines, a medicine repositioning business, announced that it had reached a licensing agreement with BMI Korea for its cancer cachexia treatment. According to the agreement, BMI Korea will co-own the global technology transfer rights of ASCA101_CC with Meta Fines. It will have the option to license the product in certain regions, including Korea and Southeast Asia. BMI Korea will pay Meta Fines USD 1.51 million up front, followed by 46 billion won in tiered milestone payments. ASCA101_CC is a pipeline that targets cancer cachexia.

Cancer Cachexia Market Report Analysis:

Market Expansion Strategies

·For instance, in January 2023, Endevia Bio, rises USD 10 million Series B funding for the advance development of TCMCB07 for the treatment of cachexia. It was designed as a first-in-class peptide drug with the ability to cross the blood-brain barrier and act on unreachable target receptors to modulate the body’s behavioral and metabolic response to chronic illness. The advancing in the clinical development of TCMCB07, aimed to help millions of cachexia patients.

·For instance, in April 2021, Ono Pharamceutical Co., Ltd., launched Adlumiz, ghrelin receptor agonist, for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer in Japan. Adlumiz was used in combination with other cancer treatments, such as chemotherapy, radiation, or immunotherapy, of cancer cachexia. Combining Adlumiz with these treatments, help patients to manage side effects such as weight loss and fatigue.

Browse ∼60 market data tables and ∼35 figures through ∼140 slides and in-depth TOC on “Cancer cachexia Market, By Product (Progestogens, Corticosteroids, Combination Therapies, and Others), Mechanism of Action (Appetite Stimulators, Weight Loss Stabilizers), Distributional Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Region - Trends, Analysis, and Forecast till 2034”

For more insights into the Cancer cachexia Market and its future trends, visit the link: https://www.prophecymarketinsights.com/market_insight/cancer-cachexia-market-5570

Competitive Landscape of Cancer Cachexia Market:

The key players operating in the cancer cachexia market are AbbVie Inc., Actimed Therapeutics, Aeterna Zentaris Inc., ANI Pharmaceuticals Inc., Aphios Corporation, Aveo Pharmaceuticals Inc., Bristol-Myers Squibb Company, Helsinn Group, Hikma Pharmaceuticals PLC, Merck & Co. Inc., Mylan N.V., Pfizer Inc., TCI Peptide Therapeutics, and Teva Pharmaceutical Industries Ltd.